FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379281034> ?p ?o ?g. }

• W4379281034 endingPage "8594" @default.
• W4379281034 startingPage "8594" @default.
• W4379281034 abstract "8594 Background: Transcriptomic subtyping holds promise for personalized therapy in SCLC, but intratumoral transcriptomic heterogeneity and its clinical significance remain poorly defined. In this study, we aimed to assess transcription factor defined subtypes within multiple regions of intact tissues and identify gen sets associated with long-term chemo-immunotherapy benefit. Methods: We assessed baseline FFPE tumors from 32 ES-SCLC patients enrolled in the IMfirst clinical trial (EudraCT: 2019-002784-10). We used GeoMx DSP to perform transcriptomic analysis from multiple intratumoral regions of interest (ROIs). We used an assay with +1800 genes (GeoMx CTA) plus custom-designed mRNA probes targeting subtype-defining transcription factors not included in the CTA assay (POU2F3, NEUROD1, and YAP1). Custom probes were quantitatively validated using FFPE cell lines. Results: We profiled 175 ROIs from 32 tumors. Cluster analysis based on the expression of ASCL1, NEUROD1, POU2F3, and YAP1 showed that all samples clustered within 4 groups: SCLC-A (76 ROIs [43%]), SCLC-N (31 ROIs [18%]), SCLC-P (18 ROIs [10%]), and SCLC-Y (50 ROIs [29%]). ASCL1 was the most abundantly expressed transcription factor, prevailed in the SCLC-A subtype, and showed inverse correlation with POU2F3 (r=-0.55, p<0.0001) and YAP1(r=-0.70, p<0.0001). YAP1 was expressed at low levels and was more broadly distributed across all 4 subtypes. Differential expression and gene set enrichment analysis (GSEA) using linear mixed models revealed that SCLC-A subtype was enriched in cell cycle and DNA damage repair genes, and showed repression of multiple gene sets associated with anti-tumor immune response. In contrast, SCLC-Y subtype showed the opposite pattern. The SCLC-P subtype was also enriched in genes related to cancer antigens and T-cell checkpoints. Most patients (n=18, 56%) had tumors with coexistence of more than one subtype, not evident through morphological inspection. Combined SCLC-A and SCLC-Y subtypes was the most common mixed phenotype (n=8, 25%). Four patients (13%) had tumors with co-existence of three subtypes. Transcriptional subtypes, subtype-defining transcription factors as single genes, or the presence of subtype heterogeneity, were not associated with outcomes. Gene sets involved in mitochondrial metabolism and MHC class I antigen presentation were the highest enriched pathways in tumors from patients with sustained benefit (time to progression ³ 12 months). Conclusions: This study reveals substantial intratumoral transcriptomic subtype heterogeneity in human SCLC. In this limited sample set, we did not observe outcome association for transcriptional subtypes. Our findings related to long-term chemo-immunotherapy benefit require validation in independent cohorts." @default.
• W4379281034 created "2023-06-05" @default.
• W4379281034 creator A5003518821 @default.
• W4379281034 creator A5006278406 @default.
• W4379281034 creator A5014364032 @default.
• W4379281034 creator A5014900800 @default.
• W4379281034 creator A5022099986 @default.
• W4379281034 creator A5030405170 @default.
• W4379281034 creator A5041861170 @default.
• W4379281034 creator A5051145057 @default.
• W4379281034 creator A5052765751 @default.
• W4379281034 creator A5056402824 @default.
• W4379281034 creator A5062737461 @default.
• W4379281034 creator A5063439924 @default.
• W4379281034 creator A5067601551 @default.
• W4379281034 creator A5071838311 @default.
• W4379281034 creator A5073917049 @default.
• W4379281034 creator A5076643417 @default.
• W4379281034 creator A5076849551 @default.
• W4379281034 creator A5080841299 @default.
• W4379281034 creator A5082318012 @default.
• W4379281034 creator A5092083225 @default.
• W4379281034 date "2023-06-01" @default.
• W4379281034 modified "2023-10-18" @default.
• W4379281034 title "Spatially resolved multi-region transcriptomic subtyping and assessment of gene expression profiles associated with long-term benefit from chemo-immunotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC)." @default.
• W4379281034 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.8594" @default.
• W4379281034 hasPublicationYear "2023" @default.
• W4379281034 type Work @default.
• W4379281034 citedByCount "0" @default.
• W4379281034 crossrefType "journal-article" @default.
• W4379281034 hasAuthorship W4379281034A5003518821 @default.
• W4379281034 hasAuthorship W4379281034A5006278406 @default.
• W4379281034 hasAuthorship W4379281034A5014364032 @default.
• W4379281034 hasAuthorship W4379281034A5014900800 @default.
• W4379281034 hasAuthorship W4379281034A5022099986 @default.
• W4379281034 hasAuthorship W4379281034A5030405170 @default.
• W4379281034 hasAuthorship W4379281034A5041861170 @default.
• W4379281034 hasAuthorship W4379281034A5051145057 @default.
• W4379281034 hasAuthorship W4379281034A5052765751 @default.
• W4379281034 hasAuthorship W4379281034A5056402824 @default.
• W4379281034 hasAuthorship W4379281034A5062737461 @default.
• W4379281034 hasAuthorship W4379281034A5063439924 @default.
• W4379281034 hasAuthorship W4379281034A5067601551 @default.
• W4379281034 hasAuthorship W4379281034A5071838311 @default.
• W4379281034 hasAuthorship W4379281034A5073917049 @default.
• W4379281034 hasAuthorship W4379281034A5076643417 @default.
• W4379281034 hasAuthorship W4379281034A5076849551 @default.
• W4379281034 hasAuthorship W4379281034A5080841299 @default.
• W4379281034 hasAuthorship W4379281034A5082318012 @default.
• W4379281034 hasAuthorship W4379281034A5092083225 @default.
• W4379281034 hasConcept C104317684 @default.
• W4379281034 hasConcept C121608353 @default.
• W4379281034 hasConcept C126322002 @default.
• W4379281034 hasConcept C143998085 @default.
• W4379281034 hasConcept C150194340 @default.
• W4379281034 hasConcept C162317418 @default.
• W4379281034 hasConcept C199360897 @default.
• W4379281034 hasConcept C2777701055 @default.
• W4379281034 hasConcept C2779733811 @default.
• W4379281034 hasConcept C2780219982 @default.
• W4379281034 hasConcept C41008148 @default.
• W4379281034 hasConcept C502942594 @default.
• W4379281034 hasConcept C54355233 @default.
• W4379281034 hasConcept C71924100 @default.
• W4379281034 hasConcept C83852419 @default.
• W4379281034 hasConcept C86339819 @default.
• W4379281034 hasConcept C86803240 @default.
• W4379281034 hasConceptScore W4379281034C104317684 @default.
• W4379281034 hasConceptScore W4379281034C121608353 @default.
• W4379281034 hasConceptScore W4379281034C126322002 @default.
• W4379281034 hasConceptScore W4379281034C143998085 @default.
• W4379281034 hasConceptScore W4379281034C150194340 @default.
• W4379281034 hasConceptScore W4379281034C162317418 @default.
• W4379281034 hasConceptScore W4379281034C199360897 @default.
• W4379281034 hasConceptScore W4379281034C2777701055 @default.
• W4379281034 hasConceptScore W4379281034C2779733811 @default.
• W4379281034 hasConceptScore W4379281034C2780219982 @default.
• W4379281034 hasConceptScore W4379281034C41008148 @default.
• W4379281034 hasConceptScore W4379281034C502942594 @default.
• W4379281034 hasConceptScore W4379281034C54355233 @default.
• W4379281034 hasConceptScore W4379281034C71924100 @default.
• W4379281034 hasConceptScore W4379281034C83852419 @default.
• W4379281034 hasConceptScore W4379281034C86339819 @default.
• W4379281034 hasConceptScore W4379281034C86803240 @default.
• W4379281034 hasIssue "16_suppl" @default.
• W4379281034 hasLocation W43792810341 @default.
• W4379281034 hasOpenAccess W4379281034 @default.
• W4379281034 hasPrimaryLocation W43792810341 @default.
• W4379281034 hasRelatedWork W1971124177 @default.
• W4379281034 hasRelatedWork W2009966535 @default.
• W4379281034 hasRelatedWork W2102579905 @default.
• W4379281034 hasRelatedWork W2734403094 @default.
• W4379281034 hasRelatedWork W3012091774 @default.
• W4379281034 hasRelatedWork W3097825150 @default.
• W4379281034 hasRelatedWork W3201422854 @default.
• W4379281034 hasRelatedWork W4247273247 @default.
• W4379281034 hasRelatedWork W4294669864 @default.
• W4379281034 hasRelatedWork W4294954873 @default.

• next